

## Literaturauswahl

### Tryptophan-Immunoabsorption bei neurologischen Erkrankungen

#### Multiple Sklerose

- **Pfeuffer et al.** Immunoabsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. *J Neuroinflammation* 2022; 19:220 [open access](#)
- **Schimrigk et al.** Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoabsorption – observational multicenter study with 147 patients. *Eur Neurol* 2016; 75:300-306
- **Heigl et al.** Immunoabsorption in steroid-refractory multiple sclerosis: Clinical experience in 60 patients. *Atheroscler Suppl* 2013; 4:167-173
- **Koziolek et al.** Immunoabsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. *Journal of Neuroinflammation* 2012; 9:80 [open access](#)
- **Trebst et al.** Immunoabsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. *Blood Purif* 2012; 33:1-6
- **Mauch et al.** Immunoabsorption bei steroidrefraktärem Schub der Multiplen Sklerose. *Nervenarzt* 2011; 82:1590-1595

#### Schwangerschaft und Stillphase

- **Hoffmann et al.** Tryptophan immunoabsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. *Ther Adv Neurol Disord* 2018; 11:1-12 [open access](#)
- **Hoffmann et al.** Tryptophan-Immunoabsorption bei Multipler Sklerose und Neuromyelitis optica. Therapieoption bei akuten Schüben in der Schwangerschaft und Stillphase. *Nervenarzt* 2015; 86:179-186

#### Kinder

- **Cramer et al.** Immunoabsorption is equally effective as plasma exchange in paediatric neuroimmunological disorders. A retrospective multicentre study. *Eur J Paediatr Neurol* 2025; 54:58-63
- **Koziolek et al.** Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease. *Blood Purif* 2013; 36:92-97

#### Neuromyelitis optica Spectrum Erkrankungen (NMOSD)

- **Heigl et al.** Immunoabsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder. *Ther Adv Neurol Disord* 2023;16:1-12 [open access](#)
- **Liu et al.** A prospective study on tryptophan immunoabsorption in AQP4 antibody-positive neuromyelitis optica spectrum disorders. *J Clin Apher* 2022;1-8
- **Kleiter et al.** Apheresis therapies for NMOSD attacks. *Neurol Neuroimmunol Neuroinflamm* 2018; e504. Doi:10.1212 /NXI.0000000000000504 [open access](#)
- **Kleiter et al.** Neuromyelitis optica: evaluation of 871 attacks and 1.153 treatment courses. *Ann Neurol* 2016; 79(2):206-216
- **Faissner et al.** Immunoabsorption in patients with neuromyelitis optica spectrum disorders. *Ther Adv Neurol Disord* 2016; 4:281-286 [open access](#)
- **Kobayashi et al.** Immunoabsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase. *J Clin Apher* 2015;30(1):43-45

#### MOGAD

- **Schwake et al.** Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks. *J Neurol Neurosurg Psychiatry* 2025;96:639-646
- **Wang et al.** Immunoabsorption therapy for myelin oligodendrocyte glycoprotein antibody-associated disease. *Ther Apher Dial* 2025; 0:1-6

#### CIDP

- **Lieker et al.** A prospective study comparing tryptophan immunoabsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. *J Clin Apher* 2017; 32(6):486-493
- **Galldiks et al.** Immunoabsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. *Eur Neurol* 2011; 66:183-189

## Literaturauswahl

### Tryptophan-Immunoadsorption bei neurologischen Erkrankungen

#### Guillain-Barré-Syndrom

- **Galldiks et al.** Selective immune adsorption treatment of severe Guillain Barré syndrome in the intensive care unit. *Neurocrit Care* 2009; 11 (3): 317-32.
- **Seta et al.** Factors influencing outcome in Guillain-Barré syndrome: comparison of plasma adsorption against other treatments. *Clin Neurol Neurosurg* 2005; 107: 491-496
- **Arakawa et al.** Immunoabsorption therapy for a child with Guillain-Barré syndrome subsequent to Mycoplasma infection: a case study. *Brain & Development* 2005; 431-433
- **Okamiya et al.** Tryptophan-immobilized column-based immunoabsorption as the choice method for plasmapheresis in Guillain-Barré syndrome. *Ther Apher Dial* 2004 8:248-253
- **Jimenez et al.** Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barré syndrome. *Transfus Sci* 1993; 14:9-11

#### Autoimmune Enzephalitis

- **Dogan Onugoren et al.** Immunoabsorption therapy in autoimmune encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2016; 3(2): e207 [open access](#)
- **Heine et al.** Immunoabsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. *J Neurol* 2016; DOI 10.1007/s0041-016-8277-y
- **Fassbender et al.** Immunoabsorption for autoimmune encephalitis. *Atheroscler Suppl* 2017; 30:257-263
- **Köhler et al.** Tryptophan immunoabsorption for the treatment of autoimmune encephalitis. *Eur J Neurol* 2015; 22:203-206
- **Ehrlich et al.** Therapeutische Apherese bei autoimmuner Enzephalitis - Eine bundesweite Datenerhebung. *Nervenarzt* 2013; 84:498-507

#### Myasthenia gravis

- **Dahhan F & Behnke S.** Langzeitimmunoabsorption nach myasthener Krise in der Schwangerschaft. P23 *Journal für Anästhesie und Intensivbehandlung* 1/2020
- **Schneider-Gold et al.** Immunoabsorption versus plasma exchange versus combination for treatment of myasthenic deterioration. *Ther Adv Neurol Disord* 2016; 4:297-303 [open access](#)
- **Köhler et al.** A randomised and controlled clinical study comparing immunoabsorption and plasma exchange in myasthenic crisis. *J Clin Apher* 2011; 26:347-355
- **Wagner et al.** Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunoabsorption, *Dtsch Med. Wochenschr* 2008; 133: 2377-2382
- **Grob et al.** Treatment of myasthenia gravis by immunoabsorption of plasma. *Neurology* 1995; 45:338-344

#### Lambert-Eaton Syndrom

- **Sauter et al.** A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoabsorption in a patient with Lambert-Eaton syndrome. *Ther Apher Dial* 2010; 14(3):364-367

#### Langzeittherapie: Wirksamkeit und Verträglichkeit

- **Heigl et al.** Immunoabsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder. *Ther Adv Neurol Disord* 2023;16:1-12 [open access](#)
- **Dahhan F & Behnke S.** Langzeitimmunoabsorption nach myasthener Krise in der Schwangerschaft. P23 *J für Anästhesie u. Intensivbeh.* 1/2020
- **Galldiks et al.** Immunoabsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. *Eur Neurol* 2011; 66:183-189
- **Wagner et al.** Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunoabsorption, *Dtsch Med. Wochenschr* 2008;133: 2377-2382

## Literaturauswahl

### Tryptophan-Immunoabsorption bei neurologischen Erkrankungen

#### Immunmodulation nach Tryptophan-Immunoabsorption

- **Wakabayashi et al.** Tryptophan-immunoabsorption plasmapheresis regulates PMN-MD suppressor cells and pro-inflammatory cytokines. *Ther Apher* 2024;1-9
- **Pfeuffer et al.** Immunoabsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses. *J Neuroinflammation* 2022; 19:220 [open access](#)
- **Boedecker et al.** Immunoabsorption and plasma exchange – efficient treatment options for neurological autoimmune diseases. *J Clin. Apher* 2022; 37: 70-81

#### Vorteile Tryptophan-Immunoabsorption versus Plasmaaustausch

- **Boedecker et al.** Immunoabsorption and plasma exchange – efficient treatment options for neurological autoimmune diseases. *J Clin. Apher* 2022;37: 70-81
- **Taylan et al.** Safety of therapeutic apheresis in children and adolescents. *Frontiers in Pediatrics* 2022; 10:850819 [open access](#)
- **Boss et al.** Severe and long-lasting alterations of albumin redox state by plasmapheresis. *Sci Rep* 2022 12(1):12165 [open access](#)
- **Klinge M et al.** Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness. *Scientific reports* 2020; 10:7925 [open access](#)
- **Schneider-Gold et al.** Immunoabsorption versus plasma exchange versus combination for treatment of myasthenic deterioration. *Ther Adv Neurol Disord* 2016; 4:297-303 [open access](#)
- **Koessler et al.** The effect of immunoabsorption with the immusorba TR-350 on coagulation compared to plasma exchange. *Vox Sanguinis* 2015; 108:46-21
- **Köhler et al.** A randomised and controlled clinical study comparing immunoabsorption and plasma exchange in myasthenic crisis. *J Clin Apher* 2011; 26:347-355

#### Leitlinien und Standards

- **Schettler et al.** Standard der Therapeutischen Apherese 2025 der Deutschen Gesellschaft für Nephrologie e.V. in Zusammenarbeit mit der Gesellschaft für pädiatrische Nephrologie e.V. <https://www.dgfn.eu/apherese-standard.html>
- **Laura Connelly-Smith et al.** Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. *J Clin Apher* 2023; 38(2):77-278. doi: 10.1002/jca.22043.
- **Sommer, Pitarokoili et al.** Therapie immunvermittelter Neuropathien 2025. <https://www.dgn.org/leitlinien>
- **Hemmer et al.** Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen 2024. <https://www.dgn.org/leitlinien>
- **Köhler et al.** Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie. *DGNeurologie* 2019; 1:15-33
- **Wiendl et al.** Diagnostik und Therapie myasthener Syndrome 2023. <https://www.dgn.org/leitlinien>



Scannen Sie den QR-Code für weitere Informationen:

